Phase 1 data reported on solbinsiran (LY3561774) indicate the agent’s potential as a therapeutic option for inhibiting ANGPTL3 synthesis.1
Educational partners and supporters
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
